TGA dismisses Vyvanse concerns

Investigation into potential lack of effectiveness, quality and safety of Vyvanse finds no issues of concern  Social media commentary questioning the effectiveness and safety of Vyvanse (lisdexamfetamine dimesilate) are unfounded, testing by the Therapeutic Goods Administration (TGA) suggests.   The medicines regulator announced today (Friday 26 September 2025) that an investigation into the attention deficit